Design Therapeutics (DSGN) News Today

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 3,560,000 shares, a growth of 16.7% from the July 15th total of 3,050,000 shares. Based on an average daily volume of 205,600 shares, the days-to-cover ratio is currently 17.3 days. Approximately 10.7% of the shares of the company are short sold.

Vanguard Group Inc. raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 29.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,285,962 shares of the company's stock after buying an addit

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director Arsani William sold 814,874 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $4.25, for a total value of $3,463,214.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Design Therapeutics in a report issued on Monday, August 5th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.87) per share

Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) posted its earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02.

Acadian Asset Management LLC raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 123.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 403,546 shares of the company's stock af

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendat

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has earned a consensus recommendation of "Hold" from the six analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the comp

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recom

Piper Sandler upgraded Design Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $6.00 to $12.00 in a report on Tuesday.

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,390,000 shares, a growth of 7.2% from the March 31st total of 2,230,000 shares. Based on an average daily trading volume, of 258,100 shares, the short-interest ratio is currently 9.3 days. Approximately 7.2% of the company's stock are short sold.

BML Capital Management LLC bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,029,478 shares of

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,140,000 shares, a decline of 24.9% from the February 29th total of 2,850,000 shares. Approximately 6.5% of the shares of the company are sold short. Based on an average daily volume of 259,700 shares, the short-interest ratio is presently 8.2 days.

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director John P. Schmid purchased 9,156 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the acquisition, the director now owns 9,156 shares in the company, valued at approximately $33,144.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Analysts at Wedbush issued their FY2026 earnings estimates for shares of Design Therapeutics in a research report issued on Wednesday, March 20th. Wedbush analyst L. Chico expects that the company will post earnings of ($1.27) per share for

Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Equities researchers at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for Design Therapeutics in a report issued on Tuesday, March 19th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnin

Royal Bank of Canada restated a "sector perform" rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday.

Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been given a consensus recommendation of "Hold" by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation. The average 12-m